1. Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018 Subject(s): Amyloidosis, Familial -- drug therapyRNA, Small Interfering -- therapeutic useAmyloid Neuropathies, Familial -- drug therapyAmyloidosis, Familial -- complicationsClinical Trials as TopicCost-Benefit AnalysisRNA, Small Interfering -- adverse effectsRNA, Small Interfering -- economicsTreatment OutcomeHumansUnited States
